Publications by authors named "Vikash Pal"
Importance: The role of olanzapine has not been adequately evaluated in moderately emetogenic chemotherapy (MEC) regimens with or without neurokinin-1 receptor antagonists.
Objective: To evaluate whether addition of olanzapine to an MEC regimen reduces nausea, vomiting, and use of nausea rescue medications among patients with solid malignant tumors.
Design, Setting, And Participants: This multicenter, open-label phase 3 randomized clinical trial included patients aged 18 years or older with solid malignant tumors who were receiving oxaliplatin-, carboplatin-, or irinotecan-based chemotherapy.
Docetaxel-oxaliplatin-capecitabine/5-fluorouracil (DOX/F) followed by docetaxel versus oxaliplatin-capecitabine/5-fluorouracil (CAPOX/FOLFOX) in HER2-negative advanced gastric cancers.
Anant Ramaswamy Prabhat Bhargava Biswajit Dubashi Anuj Gupta Akhil Kapoor Vikash Pal Deepali Chaugule
JNCI Cancer Spectr
July 2024
Article Synopsis
- The study aimed to assess if adding docetaxel (D) to standard chemotherapy regimens improved overall survival (OS) in patients with advanced HER2-negative gastroesophageal junction and gastric adenocarcinomas.
- Out of 324 patients enrolled, the analysis showed that FOLFOX/CAPOX provided a median OS of 10.1 months, while the DOF/DOX regimen resulted in 8.9 months, with no significant survival advantage from the addition of docetaxel (P = .70).
- The study also noted higher rates of severe neutropenia and neuropathy in the DOF/DOX group and identified a surprisingly high incidence of BRCA1 and BRCA2 alterations